نتایج جستجو برای: سلولهای T مهندسی شده (CAR T Cell)
تعداد نتایج: 2678626 فیلتر نتایج به سال:
Cell therapy with T cells expressing chimeric antigen receptor (CAR-T) is a type of immunotherapy that involves the manipulation and reprogramming immune (T lymphocytes) in order to recognize kill tumor cells. For use patients, CAR-T must be manufcatured inside GMP facility according established procedure.
Background and purpose: In recent years, immunotherapy using chimeric antigen receptor T cells (CAR T cells) has been considered as a novel and promising treatment for some diseases, especially cancer. The CAR T cell production is a multi-step, complex, time-consuming, and costly process. One of the most important steps in production of CAR T cells is expansion of these cells at appropriate num...
Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...
Introduction: Today, treatment with CAR-T cells is accepted as an effective treatment for blood malignancies. CAR-T cells are autologous T cells that are engineered by gene transfer techniques to express a chimeric antigen receptor (CAR). Despite the promising results and the approval of six CAR-T cell products; these products have not yet been approved for solid tumors. In addition, the high c...
Abstract Adoptive transfer of T cells modified with a chimeric antigen receptor (CAR) are highly effective in patients hematologic malignancies. However, many relapse and CAR have shown minimal efficacy against solid tumors. Our lab others that standard designs fail to promote differentiation into canonical cell subsets. generate both type-1 type-2 cytokines simultaneously, challenging the trad...
Background and Objective: Chimeric antigen T cell receptors provide a good approach for adoptive immunotherapy of cancer. In this new kind of chimeric T cell receptor, nanobodies are replaced as variable fragment of T cell receptor. Nanobodies (VHH) are the smallest fragments of antibodies that have great homology to human VH and low immunogenic potential. VHH-hing-CD28-CD3و construct was made ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید